March 22, 2017 — An emerging approach for cancer treatment seeks to combine...
Radiation Therapy
News | Stereotactic Body Radiation Therapy (SBRT) | March 20, 2017
March 20, 2017 — Patients in their 80s and 90s who have early-stage...
News | Brachytherapy Systems | March 15, 2017
March 15, 2017 — iCAD Inc. announced that more than 3,000 early-stage breast cancer patients have been treated with...
News | Radiation Therapy | March 14, 2017
March 14, 2017 — Over half of older women with early stage breast cancer received more...
This is a single-fraction high-dose-rate prostate implant imaging and dosimetry. Image courtesy of Daniel Krauss/American Society for Radiation Oncology (ASTRO)
News | Brachytherapy Systems | March 06, 2017
March 6, 2017 — Results from a new prospective clinical trial indicate high-dose-rate (HDR)...
Image of a human brain with seven metastases, depicted here as the small colored spheres inside rectangles. Image courtesy of UCLA Jonsson Comprehensive Cancer Center.
News | Radiation Therapy | March 03, 2017
March 3, 2017 — An extensive study by University of California Los Angeles (UCLA) researchers found significant...
Brain FUS uses an array of about 1,000 elements designed to overcome attenuation issues presented by the skull and to diffuse the heating over a large area of the brain to prevent damaging healthly tissue.
Feature | Radiation Oncology | March 02, 2017 | By Dave Fornell
Focused ultrasound (FUS), also called high-...
News | Radiation Therapy | March 02, 2017
March 2, 2017 — The Internet is one of the first places patients turn to for healthcare information after receiving...
Technology | Image Guided Radiation Therapy (IGRT) | February 27, 2017
February 27, 2017 — ViewRay Inc. announced that the company received 510(k) clearance from the U.S. Food and Drug...
News | Radiation Therapy | February 17, 2017
February 17, 2017 — Accuray Inc. recently announced data from a prospective, Phase II, 17-center study which showed...
News | Radiation Therapy | February 16, 2017
February 16, 2017 — University of Missouri (MU) School of Medicine researchers compared two common postsurgical...
News | Radiation Therapy | February 14, 2017
February 14, 2017 — The American Society for Radiation Oncology (ASTRO) recently published an updated clinical...
News | Radiation Therapy | February 13, 2017
February 13, 2017 — Accuray Inc. announced that it has received Shonin approval from the Japanese Ministry of Health...
News | Proton Therapy | February 10, 2017
February 10, 2017 — Independent market research consultancy Robust Insight recently conveyed a survey commissioned...
News | Radiation Therapy | February 07, 2017
February 7, 2017 — IBA (Ion Beam Applications S.A.) recently announced the first clinical implementation of its...
News | Radiation Therapy | February 06, 2017
February 6, 2017 — Onxeo S.A. and the Institut Curie launched a series of studies on World Cancer Day (Feb. 4) aimed...
Comparative receptor autoradiography in various cancer types (A = HE staining) with I-125-JR11 (B+C) and I-125-Tyr3-octreotide (D+E). B and D are the respective total binding, C and E the respective non-specific binding. Bars = 1 mm.
I: Breast cancer. II: Renal cell cancer. III: Medullary thyroid cancer. IV: Non-Hodgkin lymphoma. V: Colon cancer. In cancers I-V, the sections were incubated with 30’000 cpm/100 μl of antagonist or agonist. Cancers I-IV show a much higher density of sst2 with the antagonist. The colon cancer V is negative. VI: Ileal NET, incubated with 10’000 cpm/100 μl of antagonist or agonist. Credit: Jean Claude Reubi, Institute of Pathology, University of Berne, Berne, Switzerland.
News | Radiation Therapy | February 06, 2017
February 6, 2017 — A study published in the February issue of...
News | Prostate Cancer | February 03, 2017
February 3, 2017 — Adding hormonal therapy to radiation treatment can significantly improve the average long-term...